227 related articles for article (PubMed ID: 20395440)
1. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
Hansel DE; Platt E; Orloff M; Harwalker J; Sethu S; Hicks JL; De Marzo A; Steinle RE; Hsi ED; Theodorescu D; Ching CB; Eng C
Am J Pathol; 2010 Jun; 176(6):3062-72. PubMed ID: 20395440
[TBL] [Abstract][Full Text] [Related]
2. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
4. Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.
Jin S; Chang IH; Kim JW; Whang YM; Kim HJ; Hong SA; Lee TJ
J Korean Med Sci; 2017 Aug; 32(8):1327-1336. PubMed ID: 28665070
[TBL] [Abstract][Full Text] [Related]
5. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
[TBL] [Abstract][Full Text] [Related]
6. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
7. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.
Wang W; Chen H; Liu Z; Qu P; Lan J; Chen H; Zou L; Qiu J
Br J Cancer; 2016 Feb; 114(3):305-13. PubMed ID: 26742010
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated p70S6K in noninvasive low-grade urothelial carcinoma of the bladder: correlation with tumor recurrence.
Kim SJ; Kim JH; Jung HS; Lee TJ; Lee KM; Chang IH
Asian J Androl; 2014; 16(4):611-7. PubMed ID: 24625880
[TBL] [Abstract][Full Text] [Related]
10. P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model.
Chi BH; Kim SJ; Seo HK; Seo HH; Lee SJ; Kwon JK; Lee TJ; Chang IH
J Korean Med Sci; 2015 Mar; 30(3):308-16. PubMed ID: 25729255
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.
Whang YM; Kim MJ; Cho MJ; Yoon H; Choi YW; Kim TH; Chang IH
J Cell Physiol; 2019 Aug; 234(8):13083-13096. PubMed ID: 30549029
[TBL] [Abstract][Full Text] [Related]
12. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925
[TBL] [Abstract][Full Text] [Related]
13. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.
Gonzalez-Roibon ND; Chaux A; Al-Hussain T; Osunkoya AO; Bezerra SM; Hicks J; Epstein JI; Netto GJ
Hum Pathol; 2013 Apr; 44(4):612-22. PubMed ID: 23084634
[TBL] [Abstract][Full Text] [Related]
15. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.
Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT
Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.
Mansure JJ; Nassim R; Chevalier S; Rocha J; Scarlata E; Kassouf W
Cancer Biol Ther; 2009 Dec; 8(24):2339-47. PubMed ID: 20061787
[TBL] [Abstract][Full Text] [Related]
17. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.
Ahmed M; Kundu GC
Mol Cancer; 2010 May; 9():101. PubMed ID: 20459645
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
